| Ip, 2021[17] | 2018 to 2019 | 121,096,335 | Physician attendances (including telehealth) | 2019-2020 | 114,089,347 (6% reduction) | 2020-2021 | 99,330,510 (18% reduction) |
| 692,021 | PSA tests | 657,468 | 2020-2021 | 706,088 |
| 135,775 | Free-to-total PSA tests | 140,024 | 156,321 |
| 31,750 | Multi-parametric MRI | 35,672 | 35,942 |
| 19,923 | Prostate biopsy | 21,453 | 21,574 |
| Ferrari, 2021[18], median (IQR) | 2016 to 2019 | 283 (271 to 288) | Vit D | Lockdown (Mar to May, 2020) | 66 (48 to 126) | | |
| 146 (129 to 147) | Total PSA | | 62% (median decrease) | | |
| 2016 to 2019 | 256 (228 to 280) | Vit D | | | Post-lockdown | 295 (267 to 322) |
| 135 (116 to 151) | Total PSA | | | | 181 (165 to 201) |
| Fallara, 2021[19] | 2017 to 2019 | 2,285 | Total cases | 2020 | 1,458 (36% fewer) | | |
| Stroman 2021[20], number of centers | | | Prostate MRI | During the pandemic | 14 (13%) centers stopped 39 (37%) centers offered with same indications 48 (46%) centers offered to selected high-risk patient group only | | |
| Before the pandemic | 68 | LATP | During the pandemic | 56 | | |
| 85 | GATP | 32 | | |
| 83 | LATRUS | 34 | | |
| Surasi 2021[21], mean (SD) per week | Before the pandemic | 26.0 (26.0) | Prostate MRI | Lockdown period | 11.6 (8.2) | After lockdown | 21.3 (25.3) |
| 7.9 (11.7) | Prostate biopsy | 2.3 (3.3) | 9.6 (8.0) |
| Pepe 2021[22] | 2019 to 2020 | 2,000 | Clinical office evaluation | 2020 to 2021 | 1,015 | | |
| 351 | Multi-parametric MRI | 85 | | |
| 485 | Prostate biopsy | 201 | | |
| 187 (38.5%) | Cancer diagnosis from biopsy | 96 (47.7%) | | |
| Kaufman 2021[23], average monthly number | Prepandemic | 465,187 | PSA tests | Early Pandemic | 295,786 (36.4% decrease) | Late Pandemic | 483,374 (3.9% increase) |
| 659 | PSA results ≥ 50 ng/mL | | 506 (23.2% decrease) | | 674 (2.3% increase) |
| 1,453 | Prostate biopsy results | | 903 (37.9% decrease) | | 1,190 (18.1% decrease) |
| 182 | Gleason score ≥ 8 | | 130 (28.6% decrease) | | 161 (11.5% decrease) |
| Nossiter 2022[24] | 2019 | 9,918/25,936 (38.2%) | Transperineal/prostate biopsy | 2020 | 10,592/16,551 (64.0%) | | |
| 2019 | 32,409 | Diagnoses | 2020 | 22,419 (30.8% reduction) | | |
| Deukeren 2022[25] | 2019 | 21,542 | Diagnoses | 2020 | 18,444 | End of 2020 | Restored to approximately 95% of expectation |
| 13,621 (63.2%) | N (%) of malignant pathology | 12,756 (69.2%) | | |